Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Venetoclax in R/R APL
NCT05881265Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute promyelocytic leukemia (APL), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Complete Remission and Complete Remission with Incomplete Recovery of Peripheral Blood Count at Day 42. Started May 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT05881265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881265.